| Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90% |
Carl Icahn is making bold moves from the lab to the tarmac. |
benzinga.com |
2025-05-16 15:28:11 |
Czytaj oryginał (ang.) |
| Illumina To Webcast Upcoming Investor Conference |
SAN DIEGO , May 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 41st Annual Bernstein Strategic Decisions Conference on May 28, 2025 Fireside chat at 11:30am Pacific Time (2:30pm Eastern Time) The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com. A replay will be posted on Illumina's website after the event and will be available for at least 30 days following. |
prnewswire.com |
2025-05-14 20:05:00 |
Czytaj oryginał (ang.) |
| Investing in Illumina (ILMN)? Don't Miss Assessing Its International Revenue Trends |
Review Illumina's (ILMN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock. |
zacks.com |
2025-05-13 14:21:48 |
Czytaj oryginał (ang.) |
| Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications |
Building on reputation for unparalleled performance, latest software delivers even greater accuracy, with 30% improvement in structural variant calling New features include easy-to-use oncology apps, enhanced multiomics pipelines, and AWS F2 support enabling faster turnaround times SAN DIEGO , May 13, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of DRAGEN™ version 4.4 software (v4.4), the industry's most comprehensive secondary analysis solution. The latest version of DRAGEN includes out-of-the-box oncology applications for clinical research and support for newly announced Illumina multiomics assays. |
prnewswire.com |
2025-05-13 13:15:00 |
Czytaj oryginał (ang.) |
| Illumina Analysts Lower Their Forecasts After Q1 Results |
Illumina, Inc. ILMN reported upbeat earnings for the first quarter, but lowered its FY25 guidance, after the closing bell on Thursday. |
benzinga.com |
2025-05-12 15:28:03 |
Czytaj oryginał (ang.) |
| Illumina: Multiple Headwinds Point To Limited Upside In 2025 |
Illumina faces significant challenges, including revenue declines, margin pressures, and geopolitical hurdles, notably from China and competition from Roche's SBX technology. Q1 2025 results were in line, but updated guidance predicts a revenue decline of 1%-3%, due to China headwinds and uncertain U.S. research funding. Despite a $100 million cost reduction program and ongoing R&D investments, Illumina's stock appears overvalued by nearly 18% based on a DCF analysis. |
seekingalpha.com |
2025-05-11 02:58:47 |
Czytaj oryginał (ang.) |
| Illumina Q1 Earnings Top Estimates, Revenues Down Y/Y, Stock Dips |
ILMN delivers better-than-expected earnings and revenues in the first quarter of 2025. |
zacks.com |
2025-05-09 13:50:42 |
Czytaj oryginał (ang.) |
| Illumina, Inc. (ILMN) Q1 2025 Earnings Call Transcript |
Illumina, Inc. (NASDAQ:ILMN ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Brian Blanchett - Interim Head of Investor Relations Jacob Thaysen - Chief Executive Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Dave Westenberg - Piper Sandler Jack Meehan - Nephron Vijay Kumar - Evercore Tycho Peterson - Jefferies Conor McNamara - RBC Capital Markets Mike Ryskin - Bank of America Kyle Mikson - Canaccord Operator Good day ladies and gentlemen, and welcome to the First Quarter 2025 Illumina Earnings Conference Call. At this time, all participants are in a listen only mode. |
seekingalpha.com |
2025-05-09 01:01:47 |
Czytaj oryginał (ang.) |
| Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates |
Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-05-09 00:30:40 |
Czytaj oryginał (ang.) |
| Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates |
Illumina (ILMN) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.09 per share a year ago. |
zacks.com |
2025-05-08 23:00:32 |
Czytaj oryginał (ang.) |
| Unveiling Illumina (ILMN) Q1 Outlook: Wall Street Estimates for Key Metrics |
Beyond analysts' top -and-bottom-line estimates for Illumina (ILMN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025. |
zacks.com |
2025-05-05 14:21:12 |
Czytaj oryginał (ang.) |
| Illumina (ILMN) Earnings Expected to Grow: Should You Buy? |
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-05-01 15:07:15 |
Czytaj oryginał (ang.) |
| Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development |
First real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapies Dataset will advance development of GLP-1 therapies in new indications and accelerate discovery of novel drug targets in patients who are unresponsive to therapies SAN DIEGO , May 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Ovation.io, Inc., an organization dedicated to building best-in-class multiomics datasets, today announced the development of the largest commercially available clinical multiomic dataset from 25,000 patients treated with glucagon-like peptide-1 (GLP-1) receptor agonist therapies. The dataset will be made available to the pharma community to advance drug discovery and development. |
prnewswire.com |
2025-05-01 13:15:00 |
Czytaj oryginał (ang.) |
| Resmed Names Salli Schwartz as Chief Investor Relations Officer |
Former Illumina, MSCI, and Moody's executive brings extensive experience leading engagement with the global investment community Former Illumina, MSCI, and Moody's executive brings extensive experience leading engagement with the global investment community |
globenewswire.com |
2025-04-21 21:00:00 |
Czytaj oryginał (ang.) |
| Target Validation for Genetic Targets Innovation Research Report 2025: 14,172 Deals Totaling $11.4 Billion - BGI biotech and illumina are Among the Leaders with Strong Portfolios |
Dublin, April 18, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: Target validation for genetic targets" report has been added to ResearchAndMarkets.com's offering. |
globenewswire.com |
2025-04-18 14:25:00 |
Czytaj oryginał (ang.) |
| Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation |
Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO , April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation. The collaboration will combine leading Illumina AI technologies with Tempus's comprehensive multimodal data platform to train genomic algorithms and ultimately accelerate clinical adoption of molecular testing for patients. |
prnewswire.com |
2025-04-15 13:15:00 |
Czytaj oryginał (ang.) |
| Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025 |
SAN DIEGO , April 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2025 following the close of market on Thursday, May 8, 2025. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. |
prnewswire.com |
2025-04-10 20:05:00 |
Czytaj oryginał (ang.) |
| Illumina price target lowered to $85 from $90 at Citi |
Citi lowered the firm's price target on Illumina to $85 from $90 and keeps a Neutral rating on the shares as part of a Q1 preview for the life science tools and diagnostics group. The firm believes tariffs and the National Institutes of Health spending cuts are overhands on the sector. |
https://thefly.com |
2025-04-07 10:19:02 |
Czytaj oryginał (ang.) |
| Here's Why Illumina (ILMN) is a Strong Value Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-04-04 14:46:40 |
Czytaj oryginał (ang.) |
| Corvex's Meister joins the board at Illumina. Here's how he can create value for shareholders |
Keith Meister, Corvex Management's chief investment officer, will join Illumina's board starting March 28. He's no stranger to the world of biotech. |
cnbc.com |
2025-03-29 09:25:27 |
Czytaj oryginał (ang.) |
| Illumina, Inc. (ILMN) AGBT Investor Session Conference (Transcript) |
Illumina, Inc. (NASDAQ:ILMN ) AGBT Investor Session Conference February 25, 2025 11:00 AM ET Company Participants Salli Schwartz - Head of Investor Relations Jacob Thaysen - Chief Executive Officer Steve Barnard - Chief Technology Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Subbu Nambi - Guggenheim Securities Dan Brennan - TD Cowen Dan Arias - Stifel Puneet Souda - SVB Securities Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies LLC Patrick Donnelly - Citi Tejas Savant - Morgan Stanley Jack Meehan - Nephron Research Kyle Mikson - Canaccord Genuity Salli Schwartz Welcome. Thank you for your patience while we got started. |
seekingalpha.com |
2025-02-25 21:43:05 |
Czytaj oryginał (ang.) |
| ILMN Stock Might Rise From Collaboration With Broad Clinical Labs |
Illumina Collaborates with Broad Clinical Labs to set the standard for scalable single-cell research and accelerate discovery in areas such as disease modeling and drug development. |
zacks.com |
2025-02-24 13:15:27 |
Czytaj oryginał (ang.) |
| Illumina transforms multiomic research with new technologies to unlock deeper understanding of biology |
Company expands multiomics portfolio with new roadmap technologies spanning genomics, spatial, single cell, CRISPR, and methylation, as well as a new multimodal data analysis platform Built on Illumina's powerful sequencers, new, disruptive omics solutions surpass industry standards for quality, scale, accuracy, and replicability SAN DIEGO , Feb. 24, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) has unveiled a series of roadmap innovations, establishing the industry's largest portfolio of omics solutions and sequencing applications. The solutions – spanning genomics, spatial transcriptomics, single cell analysis, CRISPR technologies, epigenetics, and data analytics software – will enable researchers to derive breakthrough insights around the drivers of disease. |
prnewswire.com |
2025-02-24 11:15:00 |
Czytaj oryginał (ang.) |
| Illumina and Broad Clinical Labs usher in new era of drug discovery with collaboration to rapidly scale single-cell solutions |
Longstanding partners bring together end-to-end workflows and leading CRISPRPerturb-seq technologies setting a standard for single-cell studies and enabling a 5billion single-cell atlas ecosystem within three years SAN DIEGO , Feb. 21, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing and array-based technologies, today announced a collaboration with Broad Clinical Labs to rapidly streamline and scale single-cell projects with cutting-edge tools and workflows. Together, the longstanding partners will set the standard for scalable single-cell research and accelerate the development of a 5 billion cell atlas within the next three years. |
prnewswire.com |
2025-02-21 11:15:00 |
Czytaj oryginał (ang.) |
| Illumina unveils first-of-its-kind spatial transcriptomics technology |
Broad Institute to collaborate on flagship project tapping Illumina's new spatial technology At AGBT, customers will present data demonstrating unparalleled scale and sensitivity in research spanning pulmonary fibrosis, prostate cancer, and 3D reconstructions of mouse brains Company expands software portfolio to decode multimodal data with Illumina Connected Multiomics SAN DIEGO , Feb. 19, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced a new spatial technology program that will empower researchers to map complex tissues and understand cellular behavior at an unprecedented scale. Enabled on Illumina sequencers and a new multimodal analysis platform, Illumina's spatial technology delivers unbiased whole-transcriptome profiling with cellular resolution and high sensitivity. |
prnewswire.com |
2025-02-19 11:15:00 |
Czytaj oryginał (ang.) |
| Illumina To Webcast Upcoming Investor Session at the Advances in Genome Biology and Technology (AGBT) Conference |
SAN DIEGO , Feb. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that investors, analysts, and other interested parties can access a live webcast of its upcoming investor session at the AGBT conference. The investor fireside chat will begin at 8:00am Pacific Time (11:00am Eastern Time) on Tuesday, February 25, 2025 and will feature Jacob Thaysen (Chief Executive Officer), Ankur Dhingra (Chief Financial Officer), and Steve Barnard (Chief Technology Officer). |
prnewswire.com |
2025-02-18 18:05:00 |
Czytaj oryginał (ang.) |
| NVIDIA's Rise Puts These 3 Healthcare Stocks in the Spotlight |
ILMN, IQV and DXCM are leveraging AI advancements to drive innovation in genomics, clinical research and diabetes management. |
zacks.com |
2025-02-18 15:36:09 |
Czytaj oryginał (ang.) |
| Here's Why Illumina (ILMN) is a Strong Growth Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-02-12 12:46:10 |
Czytaj oryginał (ang.) |
| ILMN vs. ALNY: Which Stock Is the Better Value Option? |
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Illumina (ILMN) and Alnylam Pharmaceuticals (ALNY). But which of these two stocks offers value investors a better bang for their buck right now? |
zacks.com |
2025-02-11 14:40:53 |
Czytaj oryginał (ang.) |
| Why Illumina (ILMN) is a Top Value Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-02-11 12:40:34 |
Czytaj oryginał (ang.) |
| Why Illumina Stock Got Mashed on Monday |
On Monday, for the second time in as many business days, Illumina (ILMN -5.47%) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost 6% lower, during a session when the S&P 500 (^GSPC 0.67%) landed in the black with a 0.7% increase. |
fool.com |
2025-02-10 19:12:10 |
Czytaj oryginał (ang.) |
| Illumina (ILMN) International Revenue Performance Explored |
Review Illumina's (ILMN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock. |
zacks.com |
2025-02-10 12:21:32 |
Czytaj oryginał (ang.) |
| Illumina: Regulatory Risk In China And Weaker Sales Rebound Mask A Solid Rebound Of Its Profitability |
Illumina restored its profitability well: Free Cash Flow is reaching elevated levels. However, the placement of ILMN in China's unreliable entity list could have disruptive implications for its operations in the country. The maximum exposure is 7% of its sales, which is manageable. |
seekingalpha.com |
2025-02-10 09:17:32 |
Czytaj oryginał (ang.) |
| Cathie Wood Sours on Tesla and Moderna, but Likes These Stocks Instead |
Star portfolio manager Cathie Wood's Ark Investment Management filed its 13F holdings report for the fourth quarter on Feb. |
247wallst.com |
2025-02-08 09:44:28 |
Czytaj oryginał (ang.) |
| Why Illumina Stock Is Sinking Today |
Shares of Illumina (ILMN -8.97%) were falling on Friday. The company's stock was down by as much as 11.4% early in the session, and was still off by 8.7% as of 2:38 p.m. |
fool.com |
2025-02-07 17:03:00 |
Czytaj oryginał (ang.) |
| Illumina Analysts Slash Their Forecasts Following Q4 Results |
Illumina, Inc. ILMN reported better-than-expected results for its fourth quarter on Thursday. |
benzinga.com |
2025-02-07 16:22:53 |
Czytaj oryginał (ang.) |
| ILMN Q4 Earnings Miss Estimates, Stock Dips in Aftermarket |
Illumina's fourth-quarter revenues from the consumables business show robust growth. |
zacks.com |
2025-02-07 12:16:23 |
Czytaj oryginał (ang.) |
| Illumina, Inc. (ILMN) Q4 2024 Earnings Call Transcript |
Illumina, Inc. (NASDAQ:ILMN ) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Company Participants Salli Schwartz - Vice President of Investor Relations Jacob Thaysen - Chief Executive Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Vijay Kumar - Evercore ISI Dan Brennan - TD Cowen Puneet Souda - Leerink Partners Doug Schenkel - Wolfe Research Conor McNamara - RBC Capital Markets Dan Arias - Stifel Rachel Vatnsdal - JPMorgan Tejas Savant - Morgan Stanley Tycho Peterson - Jefferies David Westenberg - Piper Sandler Subha Nambi - Guggenheim Sung Ji Nam - Scotiabank Patrick Donnelly - Citi Operator Good day, ladies and gentlemen and welcome to the Fourth Quarter 2024 Illumina Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. |
seekingalpha.com |
2025-02-06 23:33:08 |
Czytaj oryginał (ang.) |
| Illumina (ILMN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates |
The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-02-06 22:01:06 |
Czytaj oryginał (ang.) |
| Illumina (ILMN) Q4 Earnings Miss Estimates |
Illumina (ILMN) came out with quarterly earnings of $0.86 per share, missing the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.14 per share a year ago. |
zacks.com |
2025-02-06 21:05:41 |
Czytaj oryginał (ang.) |
| Grail: What Lies Ahead After the Illumina Spin-Off |
This spotlight on the ROBO Global Healthcare Technology and Innovation Index highlights Grail (GRAL), a standout within the Genomics subsector. It is a key component of the $53.6 million ROBO Global Healthcare Technology and Innovation ETF (HTEC). |
etftrends.com |
2024-12-24 09:00:56 |
Czytaj oryginał (ang.) |
| Ovation.io and Illumina Collaborate to Advance Genomic Data Research |
PORTLAND, Maine--(BUSINESS WIRE)--Ovation.io, Inc., an organization dedicated to building best in class multi-omics datasets, today announced a collaboration with Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, that will work to accelerate advancements in precision medicine. The collaboration will address challenges in drug development by harnessing the power of genomic data to enable the discovery of drug targets coupled with biomarkers that incre. |
businesswire.com |
2024-12-17 11:13:00 |
Czytaj oryginał (ang.) |
| 11 Ultra SWAN Bargains That Could Thrive As The Market Soars To Record Highs |
The S&P is up 27% in 2024, including a 5.5% rally in November. The Euphoria index is at record highs, indicating investor sentiment is extremely bullish. While 2025 is likely to see much larger volatility, there are still many excellent blue-chip opportunities to buy for a potentially significant 2025. Here are 11 Ultra Sleep Well At Night quality companies that are 45% undervalued, growing at 18%, with an 85% average fundamentally justified return potential in 2025. |
seekingalpha.com |
2024-12-05 09:00:00 |
Czytaj oryginał (ang.) |
| Illumina To Webcast Upcoming Investor Conference |
SAN DIEGO , Dec. 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2024 Presentation at 9:00am Pacific Time (12:00pm Eastern Time) immediately followed by a Q&A Session to begin at approximately 9:20am Pacific Time (12:20pm Eastern Time) The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com. |
prnewswire.com |
2024-12-04 18:07:00 |
Czytaj oryginał (ang.) |
| Synaffix Licenses Metal-Free Click Chemistry Technology to Illumina for Next-Generation DNA Sequencing Applications |
Agreement grants access to Synaffix patent portfolio related to metal-free click chemistry Technology to be used in Illumina's next-generation sequencing (NGS) products AMSTERDAM , Dec. 4, 2024 /PRNewswire/ -- Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage bioconjugation platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index and beyond, today announced it has entered into a licensing agreement with Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies. |
prnewswire.com |
2024-12-04 05:30:00 |
Czytaj oryginał (ang.) |
| Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Annual Evercore ISI HealthCONx Healthcare Conference (Transcript) |
Illumina, Inc. (NASDAQ:ILMN ) Annual Evercore ISI HealthCONx Healthcare Conference December 3, 2024 9:00 AM ET Company Participants Ankur Dhingra - CFO Sallilyn Schwartz - VP of Investor Relations Conference Call Participants Vijay Kumar - Evercore ISI Vijay Kumar Great. Thanks, everyone, for joining us this afternoon. |
seekingalpha.com |
2024-12-03 18:41:50 |
Czytaj oryginał (ang.) |
| Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2 |
Myriad Genetics announces incorporation of its proprietary HRD platform in Illumina's updated comprehensive gene panel assay, TruSight™ Oncology 500 v2. |
globenewswire.com |
2024-11-20 18:30:00 |
Czytaj oryginał (ang.) |
| Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Wolfe Research 2024 Healthcare Conference (Transcript) |
Illumina, Inc. (NASDAQ:ILMN ) Wolfe Research 2024 Healthcare Conference Call November 20, 2024 9:20 AM ET Company Participants Ankur Dhingra - Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Research Doug Schenkel All right. Good morning, everybody. |
seekingalpha.com |
2024-11-20 16:09:50 |
Czytaj oryginał (ang.) |
| ILMN Stock Set to Gain From Expansion of TruSight Oncology Portfolio |
Illumina's new TSO 500 v2 assay aims to enable CGP of tumors, bolstering its TruSight Oncology portfolio. |
zacks.com |
2024-11-20 10:11:08 |
Czytaj oryginał (ang.) |
| Illumina announces expansion of TruSight Oncology portfolio |
The latest solution to enable comprehensive genomic profiling of tumors will be presented at the annual meeting of the Association of Molecular Pathology Customer-led research and presentations at the conference will deliver the latest evidence and education in tumor profiling SAN DIEGO , Nov. 19, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will release TruSight™ Oncology 500 v2 (TSO 500 v2), a new version of its flagship cancer research assay to enable comprehensive genomic profiling (CGP). The assay is currently under development, with global release planned for mid-2025. |
prnewswire.com |
2024-11-19 11:15:00 |
Czytaj oryginał (ang.) |
| Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-11-11 12:51:13 |
Czytaj oryginał (ang.) |
| Interpreting Illumina (ILMN) International Revenue Trends |
Explore how Illumina's (ILMN) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects. |
zacks.com |
2024-11-07 12:16:22 |
Czytaj oryginał (ang.) |
| Illumina To Webcast Upcoming Investor Conferences |
SAN DIEGO , Nov. 6, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conferences: Wolfe Research 2024 Healthcare Conference on November 20, 2024 Fireside chat at 6:20am Pacific Time (9:20am Eastern Time) 7th Annual Evercore HealthCONx Conference on December 3, 2024 Fireside chat at 10:20am Pacific Time (1:20pm Eastern Time) For each conference, the webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com. A replay will be posted on Illumina's website after each event and will be available for at least 30 days following. |
prnewswire.com |
2024-11-06 18:05:00 |
Czytaj oryginał (ang.) |
| Illumina: Q3 Confirms Improving Fundamentals |
Illumina is the leader in the undisputed Next Generation Sequencing market. Grail divestment is behind, enabling a margin expansion and fueling a more robust cash flow generation. The stock was down after hours, as much good news has been priced in the recent rally. |
seekingalpha.com |
2024-11-05 15:12:47 |
Czytaj oryginał (ang.) |
| ILMN Q3 Earnings Top, '24 Sales View Down, Stock Dips in Aftermarket |
Illumina's third- quarter revenues from the consumables business show robust growth, offset by the declining instruments business. |
zacks.com |
2024-11-05 12:20:24 |
Czytaj oryginał (ang.) |
| Illumina (ILMN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates |
The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2024-11-04 22:31:13 |
Czytaj oryginał (ang.) |
| Illumina, Inc. (ILMN) Q3 2024 Earnings Call Transcript |
Illumina, Inc. (NASDAQ:ILMN ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Corporate Participants Salli Schwartz - Vice President of Investor Relations Jacob Thaysen - Chief Executive Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Research Puneet Souda - Leerink Partners Vijay Kumar - Evercore ISI Dan Brennan - TD Cowen Tycho Peterson - Jefferies David Westenberg - Piper Sandler Conor McNamara - RBC Capital Markets Dan Arias - Stifel Patrick Donnelly - Citi Subha Nambi - Guggenheim Sung Ji Nam - Scotiabank Ben Mee - Stephens Dan Leonard - UBS Operator Good day, ladies and gentlemen, and welcome to the Third Quarter 2024 Illumina Earnings Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-11-04 22:09:19 |
Czytaj oryginał (ang.) |
| Illumina (ILMN) Tops Q3 Earnings and Revenue Estimates |
Illumina (ILMN) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $0.33 per share a year ago. |
zacks.com |
2024-11-04 20:56:25 |
Czytaj oryginał (ang.) |
| EARNINGS ALERT: ILMN |
Illumina (ILMN) is trading down guiding a 3% decline in revenue. George Tsilis believes the company is still notable despite the market's reaction. |
youtube.com |
2024-11-04 18:47:42 |
Czytaj oryginał (ang.) |
| Illumina Reports Financial Results for Third Quarter of Fiscal Year 2024 |
Core Illumina revenue of $1.1 billion for Q3 2024, down 2% from Q3 2023 and on a constant currency basis Core Illumina GAAP operating margin of 68.6% and non-GAAP operating margin of 22.6% for Q3 2024 Core Illumina GAAP diluted EPS of $4.03 and non-GAAP diluted EPS of $1.14 for Q3 2024 Lowered fiscal year 2024 Core Illumina revenue guidance to decline ~3% from fiscal year 2023; expect Q4 2024 Core Illumina revenue of approximately $1.07 billion Raised fiscal year 2024 Core Illumina non-GAAP operating margin guidance to a range of 21% to 21.5% Raised fiscal year 2024 Core Illumina non-GAAP diluted EPS guidance to a range of $4.05 to $4.15 SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the third quarter of fiscal year 2024. The financial results for YTD 2024 and Q3 2023 and YTD 2023 include the financial results for GRAIL which was spun off on June 24, 2024. |
prnewswire.com |
2024-11-04 18:05:00 |
Czytaj oryginał (ang.) |